HSBC raised the firm’s price target on Roche (RHHBY) to $57 from $50 and keeps a Buy rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, “even more so if AI panic kicks in.” HSBC’s preferred stocks are “growth bucket ideas,” but says “fallen angels and value could work as well.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche announces European Commission approved Gazyva/Gazyvaro
- Roche presents Lunsumio data showing potential across lymphoma treatment lines
- Roche upgraded to Neutral from Underweight at JPMorgan
- Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’
- FDA shift in drug study requirements sends trial runners lower